Neurotherapeutics Pharma Receives Investment From the Epilepsy Therapy Project

Chicago, IL, November 10, 2009 – NeuroTherapeutics Pharma, Inc., or NTP, a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, today announced that it received a $100,000 investment from the Epilepsy Therapy Project.

The Epilepsy Therapy Project invests in promising research efforts in order to help make new therapies a reality for patients, and the investment in NTP is one of the largest made in its history. “Our Board and our scientific advisors are enthusiastic about NTP and its lead compound. We view NTP’s development effort as a potentially important new therapy with a novel mechanism of action for millions of people living with uncontrolled epilepsy,” said Warren Lammert, Chairman and Co‐Founder of the Epilepsy Therapy Project and epilepsy.com.

“We are honored that the Epilepsy Therapy Project has made such a substantial investment in our technology in order to help bring this new class of therapy to people with epilepsy, their families and clinicians. The Epilepsy Therapy Project’s Board of Directors and Scientific Advisory Board are comprised of some of the most influential thought leaders in the space who have dedicated their lives to developing new therapies in this area of significant unmet need. We greatly appreciate their support and are honored to receive such an endorsement of our work,” said Dr. Stephen D. Collins, Chief Executive Officer of NeuroTherapeutics Pharma.

About NeuroTherapeutics Pharma
NeuroTherapeutics Pharma is a privately held life sciences company which is focused on the discovery and development of novel therapeutics for patients suffering from CNS disorders. NTP will file an IND for its lead compound, NTP‐2014, in the first quarter of 2010. The compound has exhibited excellent efficacy results in multiple models of epilepsy, chronic neuropathic pain and acute pain. NTP‐2014 also has demonstrated a very favorable safety profile in the IND‐enabling (GLP) subchronic toxicology studies.

NTP is financially backed by Novo Ventures and Thomas, McNerney and Partners. The company is led by a strong management team with significant drug development experience in the CNS space. Collectively, the team has filed over 15 INDs and has obtained approval for eight NDAs. The company is currently raising its Series B financing, which will advance NTP‐2014 through multiple proof‐of‐concept Phase II trials and further develop a pipeline to expand this new class of therapy. Additional information can be found at the company's website: www.ntprx.com.

About the Epilepsy Therapy Project
The Epilepsy Therapy Project is a 501(c) (3) non‐profit organization whose mission is to accelerate ideas into therapies for people living with epilepsy and seizures. Founded in 2002 by a group of parents, distinguished physicians, and researchers, the Epilepsy Therapy Project supports the commercialization of new therapies through direct grants and investments in promising academic and commercial projects. The organization has raised over six million dollars towards its mission. Learn more at: www.epilepsy.com.

Contact
Brian Williams
VP Corporate Development & Finance
(773) 444‐4181
bwilliams@ntprx.com

Kim Macher
Executive Director, Epilepsy Therapy Project
(540) 687‐8077 ext. 2
kim@epilepsytherapyproject.org

Our Mission

The mission of the Epilepsy Foundation is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives.

 
24/7 helpline
P